
LEXX Stock Forecast & Price Target
LEXX Analyst Ratings
Bulls say
Lexaria Bioscience Corp's outlook is bolstered by the anticipated enhancements in the safety profile of GLP-1 drugs, which may lead to reduced patient dropout rates and increased market acceptance. The company's cash position has improved, contributing to its ability to invest in its innovative DehydraTECH drug delivery technology, which enhances the bioavailability of a range of active pharmaceutical ingredients across various therapeutic areas. Additionally, the company projects an increase in shares outstanding to 33 million by the end of FY2026, indicating potential growth in market presence as it licenses its proprietary technology.
Bears say
Lexaria Bioscience Corp reported a significant net loss of $11.9 million for the fiscal year ending August 31, 2025, equating to a loss of $0.66 per share, indicating ongoing financial challenges. Additionally, the company experienced a net loss of $3.8 million for the third quarter of fiscal 2025, reinforcing concerns regarding its profitability and financial viability. The reductions in gastrointestinal adverse events associated with its DehydraTECH-semaglutide technology may not sufficiently offset the potential for drug discontinuation among users, further complicating the outlook for the company's licensing revenues.
This aggregate rating is based on analysts' research of Lexaria Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
LEXX Analyst Forecast & Price Prediction
Start investing in LEXX
Order type
Buy in
Order amount
Est. shares
0 shares